Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Other Non-Current Liabilities data on record, last reported at $10.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, changed N/A, while the annual FY2025 figure was $10.6 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $10.6 million in Q4 2025 per TARS's latest filing, up from $10.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $10.6 million in Q4 2025 and bottomed at $40000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 4 years is $2.6 million, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 91.94% in 2023, then surged 3915.0% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $100000.0 in 2022, then soared by 1648.0% to $1.7 million in 2023, then decreased by 29.06% to $1.2 million in 2024, then skyrocketed by 754.76% to $10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $10.6 million in Q4 2025, $10.1 million in Q3 2025, and $1.2 million in Q3 2024.